Short Bio
Dr. Anmella began his specialization in the Psychiatry and Psychology Department in the Hospital Clínic de Barcelona in 2016, and completed his specialization as a Psychiatrist in May 2020. Since then, he is working as a clinical psychiatrist and a predoctoral researcher in the Bipolar and Depressive Disorders Unit of the Hospital Clínic de Barcelona. He has also worked with Professor Michael Berk as a research fellow in The Geelong Clinic and Barwon Health, Deakin University, in 2019-2020.
He has been involved in numerous national and international research projects, and has both participated in conferences and given oral presentations on this subject. As a consequence, he has been awarded with the 3rd prize on the VI Meeting VIVE 2018 (Bilbao, Spain), sponsored by Janssen. Moreover, he has received the 2020 Biannual Grant for developing an original project to study the role of digital acoustic and language-related biomarkers in bipolar disorders from the Catalan Society of Psychiatry and Mental Health (SCPiSM) and Fundació Vila Saborit. Furthermore, he has received the award for Clinical Innovation in Technology from the Spanish Society of Psychiatry (SEP) as a representative of the Digital Innovation Group from the Bipolar and Depressive Disorders Unit, Hospital Clínic de Barcelona.During his short career, has gained experience in the clinical management of bipolar and depressive disorders and has authored 27 publications in PubMed so far with an H-index of 7.Abstract Summary
Title: Genetic Variations Associated with Treatment Response in Bipolar Depression
Our observational study included 76 patients with a retrospective index episode of major depression. They undergone pharmacogenetic testing and were evaluated with the CGI-BP-M scale. Pharmacogenetic associations were found between serotonin-norepinephrine reuptake inhibitors and the CGI-BP-M scale (B=-0.472; p=0.026), altered metabolism for selective serotonin reuptake inhibitors and the presence of (hypo)manic switch (OR=3.41; CI95%= 1.042-11.15; p=0.043), risperidone/paliperidone and lower number of adverse effects (B=-1.139; p=0.014), and altered CYP3A4 metabolism for second generation antipsychotics with a higher number of adverse effects (B=0.495; p=0.018). In conclusion, pharmacogenomic testing shows promising results on treatment effectiveness, tolerability, as well as on the predictive capability of (hypo)manic switches in bipolar disorder.
Short Bio
Lucie Bartova, born in Ostrava, Czech Republic, obtained her medical degree (MD) in 2012 at the Medical University of Vienna (MUV) in Austria. As a diploma and subsequently doctoral student at the Department of Psychiatry and Psychotherapy of the MUV, she investigated neuroimaging correlates of acute and remitted major depressive disorder (MDD) under supervision of Assoc.Prof. Priv.Doz. Dr. Lukas Pezawas (ORCID: 0000-0002-1329-6352) and received her scientific degree (PhD) in 2019. Simultaneously, she completed her psychotherapeutic training (psychoanalytic psychotherapy) and residency in psychiatry, whereby she has been involved in clinical, psychopharmacotherapeutic and neuroimaging studies focusing predominantly on MDD and schizophrenia. Under supervision of em.O.Univ.Prof. Dr.h.c.mult. Dr.med. Siegfried Kasper (ORCID: 0000-0001-8278-191X), the former head of the Department of Psychiatry and Psychotherapy of the MUV, enabling her educational opportunities which have constantly widened her scientific, clinical and personal knowledge horizon, Lucie Bartova has increasingly focused on challenging psychiatric conditions such as treatment resistant depression (TRD). She has presented her results at national and international conferences, published in known psychiatric journals, and received performance scholarship of the MUV as well as national and international travel- and research awards. She served as a member of the scientific programme & local organising committee for the CINP Thematic Meeting 2017 in Prague, Czech Republic on the topic of TRD. Since 2021 she has served as a member of the scientific committee of the 33rd CINP World Congress of Neuropsychopharmacology. In 2020 she became a member of the editorial board of the psychiatric journals „International Journal of Psychiatry in Clinical Practice“, „Frontiers in Psychiatry“, „Journal für Neurologie, Neurochirurgie und Psychiatrie“, and “JATROS Neurologie & Psychiatrie”. Since April 2021 she has served as a visiting scientist (focus: TRD) at the Psychiatry Institute at the Department of Biomedical and NeuroMotor Sciences of the University of Bologna in Italy under supervision of Prof. Alessandro Serretti (ORCID: 0000-0003-4363-3759).
Abstract Summary
Title: The Role of Sex in Patients with Major Depressive Disorder - Findings from a Cross- Sectional European Multicenter Study
Our observational, non-interventional, multicenter, cross-sectional study investigated a naturalistic sample of 1410 adult in- and outpatients with major depressive disorder (MDD) recruited by the “European Group for the Study of Resistant Depression (GSRD)” in Austria, Italy, Belgium, Germany, Greece, France, Israel, and Switzerland. While male MDD patients (N = 467) were associated with inpatient status, higher suicidality, first-line antidepressant (AD) treatment with noradrenergic- and specific serotonergic ADs, and higher mean daily doses of the administered first-line ADs, female MDD patients (N = 943) were related to outpatient status, lower suicidality, and somatic comorbidities. These clinical divergencies may support the concept of male- and female depressive syndromes and further serve as predictors of their severity and course, since they represent phenomena related to difficult-to-treat conditions in MDD. Considering sex may, hence, support clinicians in the management of challenging clinical manifestations and prevention of treatment resistance and chronicity.